LymphedemaV1, PubMed, Checkpoint, bibRecord, 005721

[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].

Identifieur interne : 005721 ( PubMed/Checkpoint ); précédent : 005720; suivant : 005722

[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].

Auteurs : W. Nocker ; W. Diebschlag ; W. Lehmacher

Source :

VASA. Zeitschrift fur Gefasskrankheiten [ 0301-1526 ] ; 1989.

RBID : pubmed:2678805

Descripteurs français

KwdFr :
- Administration par voie orale, Adulte d'âge moyen, Essais contrôlés randomisés comme sujet, Femelle, Humains, Insuffisance veineuse (traitement médicamenteux), Lymphoedème (traitement médicamenteux), Méthode en double aveugle, O-(bêta-Hydroxyéthyl)rutosides (administration et posologie), Relation dose-effet des médicaments, Rutoside (analogues et dérivés).
MESH :
- administration et posologie : O-(bêta-Hydroxyéthyl)rutosides.
- analogues et dérivés : Rutoside.
- traitement médicamenteux : Insuffisance veineuse, Lymphoedème.
- Administration par voie orale, Adulte d'âge moyen, Essais contrôlés randomisés comme sujet, Femelle, Humains, Méthode en double aveugle, Relation dose-effet des médicaments.

English descriptors

KwdEn :
- Administration, Oral, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hydroxyethylrutoside (administration & dosage), Lymphedema (drug therapy), Middle Aged, Randomized Controlled Trials as Topic, Rutin (analogs & derivatives), Venous Insufficiency (drug therapy).
MESH :
- chemical , administration & dosage : Hydroxyethylrutoside.
- chemical , analogs & derivatives : Rutin.
- drug therapy : Lymphedema, Venous Insufficiency.
- Administration, Oral, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Middle Aged, Randomized Controlled Trials as Topic.

Abstract

The antioedematous effect of 0-(beta-Hydroxylethyl)-rutoside (HR)-drinking solutions with 600, 900, 1200 and 1500 mg active substance was tested in a randomized double-blind study against placebo with 30 female patients in the change of life. The decrease of the oedemas was measured by recording the change in the leg volume. The patients valued the symptoms "tired and heavy legs", "tenseness" and "tingling sensation". After 3 months the daily taking of HR-drinking solutions showed a significant decrease of leg volume. At the end of the treatment there was no significant difference between the four verum groups.

PubMed: 2678805

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 006062
to stream PubMed, to step Curation: 006062

Links to Exploration step

pubmed:2678805

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].</title>
<author><name sortKey="Nocker, W" sort="Nocker, W" uniqKey="Nocker W" first="W" last="Nocker">W. Nocker</name>
</author>
<author><name sortKey="Diebschlag, W" sort="Diebschlag, W" uniqKey="Diebschlag W" first="W" last="Diebschlag">W. Diebschlag</name>
</author>
<author><name sortKey="Lehmacher, W" sort="Lehmacher, W" uniqKey="Lehmacher W" first="W" last="Lehmacher">W. Lehmacher</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1989">1989</date>
<idno type="RBID">pubmed:2678805</idno>
<idno type="pmid">2678805</idno>
<idno type="wicri:Area/PubMed/Corpus">006062</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">006062</idno>
<idno type="wicri:Area/PubMed/Curation">006062</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">006062</idno>
<idno type="wicri:Area/PubMed/Checkpoint">006062</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">006062</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].</title>
<author><name sortKey="Nocker, W" sort="Nocker, W" uniqKey="Nocker W" first="W" last="Nocker">W. Nocker</name>
</author>
<author><name sortKey="Diebschlag, W" sort="Diebschlag, W" uniqKey="Diebschlag W" first="W" last="Diebschlag">W. Diebschlag</name>
</author>
<author><name sortKey="Lehmacher, W" sort="Lehmacher, W" uniqKey="Lehmacher W" first="W" last="Lehmacher">W. Lehmacher</name>
</author>
</analytic>
<series><title level="j">VASA. Zeitschrift fur Gefasskrankheiten</title>
<idno type="ISSN">0301-1526</idno>
<imprint><date when="1989" type="published">1989</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Hydroxyethylrutoside (administration & dosage)</term>
<term>Lymphedema (drug therapy)</term>
<term>Middle Aged</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Rutin (analogs & derivatives)</term>
<term>Venous Insufficiency (drug therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term>
<term>Adulte d'âge moyen</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Insuffisance veineuse (traitement médicamenteux)</term>
<term>Lymphoedème (traitement médicamenteux)</term>
<term>Méthode en double aveugle</term>
<term>O-(bêta-Hydroxyéthyl)rutosides (administration et posologie)</term>
<term>Relation dose-effet des médicaments</term>
<term>Rutoside (analogues et dérivés)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hydroxyethylrutoside</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Rutin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>O-(bêta-Hydroxyéthyl)rutosides</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Rutoside</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term>
<term>Venous Insufficiency</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Insuffisance veineuse</term>
<term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term>
<term>Adulte d'âge moyen</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Femelle</term>
<term>Humains</term>
<term>Méthode en double aveugle</term>
<term>Relation dose-effet des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The antioedematous effect of 0-(beta-Hydroxylethyl)-rutoside (HR)-drinking solutions with 600, 900, 1200 and 1500 mg active substance was tested in a randomized double-blind study against placebo with 30 female patients in the change of life. The decrease of the oedemas was measured by recording the change in the leg volume. The patients valued the symptoms "tired and heavy legs", "tenseness" and "tingling sensation". After 3 months the daily taking of HR-drinking solutions showed a significant decrease of leg volume. At the end of the treatment there was no significant difference between the four verum groups.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2678805</PMID>
<DateCreated><Year>1989</Year>
<Month>11</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>1989</Year>
<Month>11</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0301-1526</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18</Volume>
<Issue>3</Issue>
<PubDate><Year>1989</Year>
</PubDate>
</JournalIssue>
<Title>VASA. Zeitschrift fur Gefasskrankheiten</Title>
<ISOAbbreviation>VASA</ISOAbbreviation>
</Journal>
<ArticleTitle>[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].</ArticleTitle>
<Pagination><MedlinePgn>235-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The antioedematous effect of 0-(beta-Hydroxylethyl)-rutoside (HR)-drinking solutions with 600, 900, 1200 and 1500 mg active substance was tested in a randomized double-blind study against placebo with 30 female patients in the change of life. The decrease of the oedemas was measured by recording the change in the leg volume. The patients valued the symptoms "tired and heavy legs", "tenseness" and "tingling sensation". After 3 months the daily taking of HR-drinking solutions showed a significant decrease of leg volume. At the end of the treatment there was no significant difference between the four verum groups.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nocker</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Diebschlag</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lehmacher</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<VernacularTitle>3monatige, randomisierte doppelblinde Dosis-Wirkungsstudie mit 0-(Beta-Hydroxyäthyl)-rutosid-Trinklösungen.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Vasa</MedlineTA>
<NlmUniqueID>0317051</NlmUniqueID>
<ISSNLinking>0301-1526</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006896">Hydroxyethylrutoside</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5G06TVY3R7</RegistryNumber>
<NameOfSubstance UI="D012431">Rutin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006896" MajorTopicYN="N">Hydroxyethylrutoside</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012431" MajorTopicYN="N">Rutin</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014689" MajorTopicYN="N">Venous Insufficiency</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2678805</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Diebschlag, W" sort="Diebschlag, W" uniqKey="Diebschlag W" first="W" last="Diebschlag">W. Diebschlag</name>
<name sortKey="Lehmacher, W" sort="Lehmacher, W" uniqKey="Lehmacher W" first="W" last="Lehmacher">W. Lehmacher</name>
<name sortKey="Nocker, W" sort="Nocker, W" uniqKey="Nocker W" first="W" last="Nocker">W. Nocker</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005721 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 005721 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:2678805
   |texte=   [A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:2678805" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].

[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki